Novartis invested heavily in research and development, spending over $6 billion in 2007 alone. It pursued both internal discovery and external partnerships. Novartis decentralized its research through institutes like NIBR that were given freedom and resources to pursue new ideas. NIBR was reorganized into disease areas and platforms to consolidate operations. Novartis also formed research institutes focused on neglected diseases and established a venture fund to support external innovation. It had over 400 collaborations and alliances to complement internal efforts, gain new technologies, and access new markets. Moving forward, Novartis needed to balance internal and external strategies to develop new drugs and reach the market quickly while maintaining its science-based approach.